Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma (NCT05471843)
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.
Who can join: Review the eligibility criteria below.
Location: University of Alabama At Birmingham Hospital — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (104 Sites)
Showing the first 25 of 104 sites.
- University of Alabama At Birmingham Hospital — Birmingham, Alabama
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia
- Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
- Des Moines Oncology Research Association — Des Moines, Iowa
- Tulane Cancer Center — New Orleans, Louisiana
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- Maryland Oncology Hematology, Pa — Columbia, Maryland
- University of Missouri Hospital, Ellis Fischel Cancer Center — Columbia, Missouri
- Nebraska Cancer Specialists — Grand Island, Nebraska
- Dartmouth Cancer Center — Lebanon, New Hampshire
- Hackensack University Medical Center — Hackensack, New Jersey
- Novant Health Hematology Charlotte — Charlotte, North Carolina
- The University of Texas Md Anderson Cancer Center — Houston, Texas
- Hospital Aleman — Buenos Aires,
- Az Sint Jan Brugge — Bruges,
- Universitair Ziekenhuis Gent — Ghent,
- University Hospitals Leuven — Leuven,
- AZ DELTA — Roeselare,
- Hospital Erasto Gaertner — Curitiba,
- Hospital Mae de Deus — Porto Alegre,
- Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp — Ribeirão Preto,
- Oncoclinicas Rio de Janeiro Sa — Rio de Janeiro,
- Instituto Americas Ensino, Pesquisa E Inovacao — Rio de Janeiro,
- Hospital Sao Rafael (Rede Dor) — Salvador,
- Hospital Beneficencia Portuguesa de Sao Paulo — São Paulo,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mantle Cell Lymphoma
- GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma — Rochester, Minnesota
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission — Birmingham, Alabama
- Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma — Vancouver, British Columbia
- Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma — Houston, Texas
- Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL — New York, New York
Explore by condition: All Mantle Cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.